Here, in this study, we successfully produced RTX-containing NPs loaded with CP and anti-Nrf2 siRNA (NP-Nrf2_siRNA-CP) and targeted CLL cells with them for the first time. Here, NFE2L2 is linked to B-cell chronic lymphocytic leukemia.